Related Experiment Video
Updated: May 12, 2026
10:00
High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
Published on: March 24, 2015
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy
Erting Tang1, Yifei Hu1,2, Guoshuai Cao1
1Pritzker School of Molecular Engineering, University of Chicago, Chicago, Illinois.
Cancer Immunology Research
|May 11, 2026
Summary
Type I interferon (IFN-I) signaling enhances chimeric antigen receptor (CAR) T-cell therapy for lymphoma. Ex vivo IFN-I treatment boosts CAR T-cell efficacy without causing in vivo toxicities, improving patient outcomes.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T-cell therapy shows promise for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
- However, a significant proportion of patients do not achieve complete response, necessitating strategies to improve therapeutic efficacy.
- Understanding the factors influencing CAR T-cell response is crucial for optimizing treatment outcomes.
Purpose of the Study:
- To identify determinants of therapeutic efficacy in CD19-directed CAR T-cell therapy for r/r DLBCL.
- To develop a novel strategy to enhance CAR T-cell efficacy by modulating type I interferon (IFN-I) signaling during manufacturing.
- To evaluate the impact of ex vivo IFN-I enhancement on CAR T-cell function and anti-tumor activity.
Main Methods:
- Single-cell transcriptomics analysis of CAR T-cell infusion products from r/r DLBCL patients with varying clinical responses.
- Ex vivo manufacturing of CAR T-cells with incorporation of low-strength IFN-I signaling.
- Assessment of IFN-I enhanced CAR T-cell cytotoxicity and efficacy against B-cell lymphoma and leukemia models.
Main Results:
- Complete responders exhibited enriched type I interferon (IFN-I) signaling signatures in their CAR T-cell infusion products compared to progressive disease patients.
- Ex vivo low-strength IFN-I signaling enhanced the cytotoxicity and efficacy of both CD28- and 4-1BB-costimulated CAR T-cells.
- The IFN-I enhancement strategy is compatible with current CAR constructs and manufacturing workflows, and avoids in vivo toxicities.
Conclusions:
- Type I interferon (IFN-I) is a potent, costimulation-independent enhancer of CAR T-cell efficacy.
- Ex vivo manufacturing incorporating IFN-I presents a translationally feasible approach to improve CAR T-cell therapy for B-cell malignancies.
- This strategy offers a potential method to overcome non-response and enhance treatment outcomes in patients with r/r DLBCL.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Immune Response Against Viral Pathogens
The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...